Please wait a minute...
J Zhejiang Univ (Med Sci)  2021, Vol. 50 Issue (6): 707-715    DOI: 10.3724/zdxbyxb-2021-0222
    
Prognostic factors in patients with persistent/recurrent differentiated thyroid carcinoma after comprehensive treatment
WANG Jianxing,YAO Yao,QIAN Yichun,YAO Weiping,CHENG Shuai,YUAN Xinyue,ZHANG Yuan()
Department of Head and Neck Surgery, the Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
Download: HTML( 2 )   PDF(3034KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Objective: To investigate the prognostic factors of patients with persistent/recurrent differentiated thyroid carcinoma (DTC) especially with external invasive persistent recurrent DTC after comprehensive treatment. Methods: The clinical data of 525 patients with persistent/recurrent DTC who underwent surgical treatment from August 2011 to June 2021 in the Department of Head and Neck Surgery of Jiangsu Cancer Hospital were retrospectively analyzed. The prognostic factors affecting overall survival (OS) and relapse-free survival (RFS) of persistent/recurrent DTC, especially external invasive persistent/recurrent DTC were analyzed. Results: Among 525 patients, 318 patients underwent thyroidectomy, 359 patients underwent central lymph node dissection, and 409 patients underwent lateral cervical lymph node dissection. Among 493 followed-up patients, 5-year OS and RFS were 95.10% and 89.60%, 8-year OS and RFS were 91.80% and 81.30%. Cox regression analysis showed that in patients with persistent/recurrent DTC after comprehensive treatment, age ≥55?years at reoperation after recurrence, male gender and distant metastasis were independent risk factors of OS (all P<0.05); while the simultaneous invasion of thyroid and lymph nodes, multiple organ invasion and the number of previous operations ≥2 were independent risk factors of RFS (allP<0.05). In patients with external invasive persistent/recurrent DTC after comprehensive treatment, age ≥55?years at reoperation after recurrence and male gender were independent risk factors of OS (bothP<0.05); while multiple organ invasion and the number of previous operations ≥2 were independent risk factors of RFS (bothP<0.05).Conclusions: Male patients aged 55?years old and above, with distant metastasis have a higher risk of poorer prognosis in persistent/recurrent DTC; while patients with simultaneous external invasion of thyroid and lymph nodes, multiple organ invasion and the number of previous operations ≥2 are more likely to relapse. For external invasive persistent/recurrent DTC, male patients aged 55?years old and above have a higher risk of poorer prognosis; while patients with multiple organ invasion and the number of previous operations ≥2 are more likely to have recurrence.



Key wordsDifferentiated thyroid carcinoma      Persistent/recurrent      Locally advanced      Multidisciplinary comprehensive treatment      Prognosis      Retrospective studies     
Received: 06 August 2021      Published: 22 March 2022
CLC:  R736.1  
Corresponding Authors: ZHANG Yuan     E-mail: yzhang1963@163.com
Cite this article:

WANG Jianxing,YAO Yao,QIAN Yichun,YAO Weiping,CHENG Shuai,YUAN Xinyue,ZHANG Yuan. Prognostic factors in patients with persistent/recurrent differentiated thyroid carcinoma after comprehensive treatment. J Zhejiang Univ (Med Sci), 2021, 50(6): 707-715.

URL:

https://www.zjujournals.com/med/10.3724/zdxbyxb-2021-0222     OR     https://www.zjujournals.com/med/Y2021/V50/I6/707


持续/复发性分化型甲状腺癌综合治疗相关预后因素分析

目的:分析持续/复发性分化型甲状腺癌(DTC)尤其是外侵型持续/复发性DTC患者综合治疗后的相关预后因素。方法:回顾性分析2011年8月至2021年6月于江苏省肿瘤医院头颈外科进行再次手术的525例DTC患者的临床资料,分析影响持续/复发性DTC尤其是外侵型持续/复发性DTC综合治疗后总生存时间和无复发生存时间的相关预后因素。结果: 525例患者中,行甲状腺区手术318例,行颈部中央淋巴结清扫359例,行颈外侧淋巴结清扫409例。493例随访患者的5年总存活率和无复发存活率分别为95.10%和89.60%,8年总存活率和无复发存活率分别为91.80%和81.30%。回归分析结果显示,复发后再次手术时55岁及以上、男性和远处转移是影响持续/复发性DTC患者综合治疗后总生存时间的独立危险因素(均P<0.05),甲状腺和淋巴结同时外侵、多器官外侵和既往手术次数2次及以上是影响持续/复发性DTC患者综合治疗后无复发生存时间的独立危险因素(均P<0.05);复发后再次手术时55岁及以上和男性是影响外侵型持续/复发性DTC患者总生存时间的独立危险因素(均P<0.05),多器官外侵和既往手术次数2次及以上是影响外侵型持续/复发性DTC患者无复发生存时间的独立危险因素(均P<0.05)。结论:复发后再次手术时55岁及以上、男性和远处转移的持续/复发性DTC患者死亡风险较高,甲状腺和淋巴结同时外侵、多器官外侵以及既往手术次数2次及以上的患者更易复发。复发后再次手术时55岁及以上和男性外侵型持续/复发性DTC患者死亡风险较高,多器官外侵和既往手术次数2次及以上的外侵型持续/复发性DTC患者更易复发。


关键词: 分化型甲状腺癌,  持续/复发,  局部晚期,  多学科综合治疗,  预后,  回顾性研究 
Figure 1 Treatment procedures for patients with persistent/recurrent differentiated thyroid carcinoma (DTC)
Figure 2 Survival curves of patients with persistent/recurrent differentiated thyroid carcinoma after comprehensive treatment

临床特征

单因素分析

多因素分析

HR

95%CI

P

HR

95%CI

P

复发后再次手术时55岁及以上

14.152

4.120~48.612

<0.01

13.595

3.816~48.432

<0.01

男性

5.687

2.047~15.798

<0.01

4.187

1.423~12.322

<0.01

不同组织外侵无

1.000

甲状腺外侵

1.931

0.581 ~ 6.419

>0.05

淋巴结外侵

1.417

0.414 ~ 4.848

>0.05

同时外侵

>0.05

器官外侵程度无

1.000

单器官外侵

2.024

0.643 ~ 6.368

>0.05

多器官外侵

1.007

0.252 ~ 4.032

>0.05

远处转移

6.154

2.500~15.151

<0.01

3.526

1.265~9.833

<0.05

再次术后碘治疗

2.765

1.123~6.810

<0.05

既往手术次数2次及以上

0.330

0.044~2.473

>0.05

Table 1 Results of regression analysis of overall survival in patients with persistent/recurrent differentiated thyroid carcinoma after comprehensive treatment

临床特征

单因素分析

多因素分析

HR

95%CI

P

HR

95%CI

P

复发后再次手术时55岁及以上

1.004

0.516~1.951

>0.05

男性

1.431

0.784~2.610

>0.05

不同组织外侵无

1.000

1.000

甲状腺外侵

1.755

0.767~4.012

>0.05

3.288

1.424~7.588

>0.05

淋巴结外侵

1.459

0.638~3.336

>0.05

3.350

1.397~8.037

>0.05

同时外侵

13.638

5.056~36.784

<0.01

12.270

4.406~34.174

<0.01

器官外侵程度无

1.000

1.000

单器官外侵

0.340

0.105~1.103

>0.05

1.304

0.301~5.646

>0.05

多器官外侵

4.346

2.079~9.089

<0.01

11.924

4.285~33.185

<0.01

远处转移

2.783

1.432~5.411

<0.01

1.039

0.431~2.504

>0.05

再次术后碘治疗

1.661

0.890~3.101

>0.05

既往手术次数2次及以上

13.853

7.401~25.927

<0.01

11.716

6.012~22.830

<0.01

Table 2 Univariate and multivariate analysis of relapse-free survival in patients with persistent/recurrent differentiated thyroid carcinoma after comprehensive treatment
Figure 3 Survival curves of patients with external invasive persistent/recurrent differentiated thyroid carcinoma after comprehensive treatment

临床特征

单因素分析

多因素分析

HR

95%CI

P

HR

95%CI

P

复发后再次手术时55岁及以上

36.209

4.761~275.402

<0.01

31.288

4.029~242.990

<0.01

男性

6.754

1.906~23.935

<0.01

4.592

1.239~17.021

<0.05

不同组织外侵 甲状腺外侵

1.000

淋巴结外侵

0.733

0.266~2.023

>0.05

同时外侵

>0.05

器官外侵程度单器官外侵

1.000

多器官外侵

0.571

0.165~1.624

>0.05

远处转移

6.377

2.312~17.587

<0.01

2.946

0.934~9.287

>0.05

再次术后碘治疗

3.045

1.104~8.397

<0.05

1.655

0.549~4.988

>0.05

既往手术次数2次及以上

0.387

0.051~2.946

>0.05

Table 3 Univariate and multivariate analysis of overall survival in patients with external invasive persistent/recurrent differentiated thyroid carcinoma after comprehensive treatment

临床特征

单因素分析

多因素分析

HR

95%CI

P

HR

95%CI

P

复发后再次手术时55岁及以上

1.076

0.515~2.244

>0.05

男性

1.290

0.660~2.519

>0.05

不同组织外侵甲状腺外侵

1.000

1.000

淋巴结外侵

0.822

0.402~1.682

>0.05

0.966

0.456~2.047

>0.05

同时外侵

7.844

3.186~19.315

<0.01

2.458

0.830~7.277

>0.05

器官外侵程度单器官外侵

1.000

1.000

多器官外侵

12.031

4.246~34.088

<0.01

8.934

3.072~26.865

<0.01

远处转移

2.981

1.456~6.103

<0.01

1.161

0.435~3.096

>0.05

再次术后碘治疗

1.737

0.874~3.454

>0.05

既往手术次数2次及以上

17.982

8.588~37.652

<0.01

16.156

7.035~37.107

<0.01

Table 4 Univariate and multivariate analysis of relapse-free survival in patients with external invasive persistent/recurrent differentiated thyroid carcinoma after comprehensive treatment
[1]   SUNGH, FERLAYJ, SIEGELR L, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]CA Cancer J Clin, 2021, 71( 3): 209-249.
doi: 10.3322/caac.21660
[2]   TRIMBOLIP, CASTELLANAM, PICCARDOA, et al.The ultrasound risk stratification systems for thyroid nodule have been evaluated against papillary carcinoma. A meta-analysis[J]Rev Endocr Metab Disord, 2021, 22( 2): 453-460.
doi: 10.1007/s11154-020-09592-3
[3]   RUIZE M L, NIUT, ZERFAOUIM, et al.A novel gene panel for prediction of lymph-node metastasis and recurrence in patients with thyroid cancer[J]Surgery, 2020, 167( 1): 73-79.
doi: 10.1016/j.surg.2019.06.058
[4]   张丽林, 赵留芳, 李晓江. 复发转移性分化型甲状腺癌诊疗进展[J]. 国际耳鼻咽喉头颈外科杂志, 2018, 42(3): 149-153
ZHANG Lilin, ZHAO Liufang, LI Xiaojiang. Progress in diagnosis and treatment of recurrent or metastatic differentiated thyriod cancer[J]. International Journal of Otolaryngology-Head and Neck Surgery, 2018, 42(3): 149-153. (in Chinese)
[5]   林岩松, 张彬, 梁智勇, 等. 复发转移性分化型甲状腺癌诊治共识[J]. 中国癌症杂志, 2015, 25(7): 481-496
LIN Yansong, ZHANG Bin, LIANG Zhiyong, et al. Consensus on diagnosis and treatment of recurrent metastatic differentiated thyroid carcinoma[J]. China Oncology, 2015, 25(7): 481-496. (in Chinese)
[6]   中华医学会内分泌学分会, 中华医学会外科学分会内分泌学组,?中国抗癌协会头颈肿瘤专业委员会,?等.甲状腺结节和分化型甲状腺癌诊治指南[J]. 中华核医学与分子影像杂志, 2013, 33(2): 96-115
Chinese Society of Endocrinology, Chinese Society of Surgery of Chinese Medical Association Endocrinology Group, Chinese Association of Head and Neck Oncology, et al. Guidelines for the diagnosis and treatment of thyroid nodules and differentiated thyroid carcinoma[J]. Chinese Journal of Nuclear Medicine and Molecular Imaging, 2013, 33(2): 96-115. (in Chinese)
[7]   AMINM B, GREENEF L, EDGES B, et al.The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging[J]CA-Cancer J Clin, 2017, 67( 2): 93-99.
doi: 10.3322/caac.21388
[8]   CARLINGT, UDELSMANR. Thyroid cancer[J]Annu Rev Med, 2014, 65( 1): 125-137.
doi: 10.1146/annurev-med-061512-105739
[9]   邹华伟, 项承. 异嗜性和多变性逆转录病毒受体1在乳头状甲状腺癌患者中表达的意义[J]. 浙江大学学报(医学版), 2021, 50(1): 90-96
ZOU Huawei, XIANG Cheng. Clinical implication of xenotropic and polytropic retrovirus receptor 1 in papillary thyroid carcinoma[J]. 2021, 50(1): 90-96. (in Chinese)
[10]   LANGB H H, LOC Y, CHANW F, et al.Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging[J]Ann Surg Oncol, 2007, 14( 2): 730-738.
doi: 10.1245/s10434-006-9207-5
[11]   SHOKOOHIA, BERTHELETE, GILLS, et al.Treatment for recurrent differentiated thyroid cancer: a canadian population based experience[J/OL]Cureus, 2020, 12( 2): e7122.
doi: 10.7759/cureus.7122
[12]   TAMS, BOONSRIPITAYANONM, AMITM, et al.Survival in differentiated thyroid cancer: comparing the AJCC cancer staging seventh and eighth editions[J]Thyroid, 2018, 28( 10): 1301-1310.
doi: 10.1089/thy.2017.0572
[13]   NIXONI J, SIMOR, NEWBOLDK, et al.Management of invasive differentiated thyroid cancer[J]Thyroid, 2016, 26( 9): 1156-1166.
doi: 10.1089/thy.2016.0064
[14]   DINGJ, WUW, FANGJ, et al.Male sex is associated with aggressive behaviour and poor prognosis in Chinese papillary thyroid carcinoma[J]Sci Rep, 2020, 10( 1): 4141.
doi: 10.1038/s41598-020-60199-9
[15]   ZAHEDIA, BONDAZL, RAJARAMANM, et al.Risk for thyroid cancer recurrence is higher in men than in women independent of disease stage at presentation[J]Thyroid, 2020, 30( 6): 871-877.
doi: 10.1089/thy.2018.0775
[16]   WANGX, WANGX L. Prognostic analysis of recurrence in children and adolescents with differentiated thyroid cancer[J]Chin Med J, 2020, 133( 19): 2281-2286.
doi: 10.1097/CM9.0000000000000910
[17]   黄璐, 李超, 王薇, 等.甲状腺癌腺外侵犯的意义及最新研究进展[J]. 中华耳鼻咽喉头颈外科杂志, 2019, 54(9): 717-720
HUANG Lu, LI Chao, WANG Wei, et al. The significance and latest progress of extrathyroidal extension of thyroid cancer[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2019, 54(9): 717-720. (in Chinese)
[18]   PARKJ, KIMK, LIMD J, et al.Male sex is not an independent risk factor for recurrence of differentiated thyroid cancer: a propensity score-matching study[J]Sci Rep, 2021, 11( 1): 14908.
doi: 10.1038/s41598-021-94461-5
[19]   HAUGENB R, ALEXANDERE K, BIBLEK C, et al.2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]Thyroid, 2016, 26( 1): 1-133.
doi: 10.1089/thy.2015.0020
[20]   TIWARIY, KRISHNAMURTHYA. Long-term outcomes of differentiated thyroid cancers with tracheal invasion: a 15-year experience[J]Indian J Cancer, 2020, 57( 4): 398-404.
doi: 10.4103/ijc.IJC_456_19
[21]   GRANIG, RAMUNDOV, VERRIENTIA, et al.Thyroid hormone therapy in differentiated thyroid cancer[J]Endocrine, 2019, 66( 1): 43-50.
doi: 10.1007/s12020-019-02051-3
[22]   TUTTLER M, AHUJAS, AVRAMA M, et al.Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association[J]Thyroid, 2019, 29( 4): 461-470.
doi: 10.1089/thy.2018.0597
[23]   YAOY, CHENGS, XUX, et al.Prognostic factors and the effect of radioiodine on patients with locally advanced differentiated thyroid cancer[J]Ann Transl Med, 2020, 8( 15): 928.
doi: 10.21037/atm-18-1301
[24]   SAMHOURIL, KRIZJ, ELSAYADK, et al.The role of radiotherapy for patients with thyroid cancer in the modern era[J]Anticancer Res, 2020, 40( 6): 3379-3386.
doi: 10.21873/anticanres.14321
[1] YU Yue,LING Shiying,SHUAI Ruixue,QIU Wenjuan,ZHANG Huiwen,LIANG Lili,JI Wenjun,LIU Yuchao,GU Xuefan,HAN Lianshu. Clinical features and outcomes of patients with cblC type methylmalonic acidemia carrying MMACHC gene c.609G>A mutation[J]. J Zhejiang Univ (Med Sci), 2021, 50(4): 436-443.
[2] SHI Jinbo,LI Xiawei,WU Yulian. Whether early stage pancreatic ductal adenocarcinoma patients could benefit from the post-operation chemotherapy regimens: a SEER-based propensity score matching study[J]. J Zhejiang Univ (Med Sci), 2021, 50(3): 375-382.
[3] ZOU Huawei,XIANG Cheng. Clinical implication of xenotropic and polytropic retrovirus receptor 1 in papillary thyroid carcinoma[J]. J Zhejiang Univ (Med Sci), 2021, 50(1): 90-96.
[4] LI Zhanlu,HUANG He,ZHANG Wenbin,WANG Min,FU Guosheng. Prognosis of patients with vulnerable plaques indicated by coronary CT angiography[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 76-81.
[5] MI Shuang,WU Yanjun,HONG Zhenghua,WANG Zhangfu,FENG Xingbing,ZHENG Guangbin. Expression of TLR4/MyD88/NF-κB pathway genes and its related inflammatory factors in secondary spinal cord injury[J]. J Zhejiang Univ (Med Sci), 2019, 48(6): 609-616.
[6] WANG Linyan,XUE Jiajin,CHEN Yi,LYU Chengjie,HUANG Shoujiang,TOU Jinfa,GAO Zhigang,CHEN Qingjiang. Clinical analysis of annular pancreas in neonates[J]. J Zhejiang Univ (Med Sci), 2019, 48(5): 481-486.
[7] MA Dong,LAI Dengming,ZHAO Xiaoxia,HU Shuqi,LYU Chengjie,HUANG Shoujiang,QIN Qi,TOU Jinfa. Therapeutic experience of type Ⅲ-b congenital intestinal atresia[J]. J Zhejiang Univ (Med Sci), 2019, 48(5): 487-492.
[8] WANG Zhan,TANG Daxing,TIAN Hongjuan,YANG Fang,WEN Hong,WANG Junmei,TAO Chang. Fetal anteroposterior renal pelvic diameter for predicting antenatal hydronephrosis requiring postnatal surgery[J]. J Zhejiang Univ (Med Sci), 2019, 48(5): 493-498.
[9] WANG Yayun,CHEN Yuan,YANG Mengmeng,XI Fangfang,ZHAN Qitao,JIANG Ying,ZHAO Baihui,LUO Qiong. Prognosis of fetuses with cystichygroma and nuchal translucency/nuchal fold thickening on prenatal echography[J]. J Zhejiang Univ (Med Sci), 2019, 48(4): 434-438.
[10] ZHANG Dandan,WANG Junmei. Prenatal diagnosis and management of fetal hepatic hemangioma[J]. J Zhejiang Univ (Med Sci), 2019, 48(4): 439-445.
[11] TONG Fan,YANG Rulai,LIU Chang,WU Dingwen,ZHANG Ting,HUANG Xinwen,HONG Fang,QIAN Guling,HUANG Xiaolei,ZHOU Xuelian,SHU Qiang,ZHAO Zhengyan. Screening for hereditary tyrosinemia and genotype analysis in newborns[J]. J Zhejiang Univ (Med Sci), 2019, 48(4): 459-464.
[12] ZHONG Wansi, CHEN Zhicai, CHEN Hongfang, XU Dongjuan, WANG Zhimin, HU Haifang, WU Chenglong, ZHANG Xiaoling, MA Xiaodong, WANG Yaxian, HU Haitao, LOU Min, Improving In-hospital Stroke Service Utilisation (MISSION) in Zhejiang Province . Effects of emergency medical service on prognosis of ischemic stroke patients treated with intravenous thrombolysis[J]. J Zhejiang Univ (Med Sci), 2019, 48(3): 241-246.
[13] CHEN Hongfang, GONG Xiaoxian, XU Dongjuan, WANG Zhimin, HU Haifang, WU Chenglong, ZHANG Xiaoling, MA Xiaodong, WANG Yaxian, HU Haitao, LOU Min, CHEN Zhicai, Improving In-hospital Stroke Service Utilisation (MISSION) in Zhejiang Province . Advanced treatment time improves outcomes of patients with ischemic stroke undergoing reperfusion therapy[J]. J Zhejiang Univ (Med Sci), 2019, 48(3): 247-253.
[14] TAO Anyang, WANG Zhimin, CHEN Hongfang, XU Dongjuan, HU Haifang, WU Chenglong, ZHANG Xiaoling, MA Xiaodong, WANG Yaxian, HU Haitao, LOU Min, Improving In-hospital Stroke Service Utilisation (MISSION) in Zhejiang Province . Association of atrial fibrillation with hemorrhagic transformation after intravenous thrombolysis in patients with ischemic stroke[J]. J Zhejiang Univ (Med Sci), 2019, 48(3): 254-259.
[15] ZHANG Congcong, LOU Min, CHEN Zhicai, CHEN Hongfang, XU Dongjuan, WANG Zhimin, HU Haifang, WU Chenglong, ZHANG Xiaoling, MA Xiaodong, WANG Yaxian, HU Haitao, Improving In-hospital Stroke Service Utilisation (MISSION) in Zhejiang Province . Analysis of intravenous thrombolysis time and prognosis in patients with in-hospital stroke[J]. J Zhejiang Univ (Med Sci), 2019, 48(3): 260-266.